tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Not yet recruiting
CT.gov ID
NCT05225233
Collaborator
(none)
124
1
2
44.9
2.8

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate if transcranial direct current stimulation (tDCS) can increase the effectiveness of cognitive training to reduce impulsivity in individuals with obesity, and to evaluate weight change with these individuals. The long-term goal of this research is to develop new treatment approaches for individuals with obesity.

Condition or Disease Intervention/Treatment Phase
  • Device: Sham Transcranial Direct Current Stimulation (tDCS)
  • Device: Active Transcranial Direct Current Stimulation (tDCS)
N/A

Detailed Description

Two-hundred forty individuals will be screened with the goal of consenting and enrolling 124 patients and 88 patients completing the study. The investigators' study protocol will consist of 13 study visits including four testing days, one before (V1), and one on the day of the tenth session of tDCS (V11) followed by the structured Group Lifestyle Class, and another test visit (V12) (2 months into the group lifestyle class), and a final test visit approximately 4 months after beginning the stimulations (V13).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transcranial Direct Current Stimulation (tDCS) With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity: A Clinical Trial
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Mar 14, 2026
Anticipated Study Completion Date :
Apr 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active tDCS with Cognitive Training

Participants will receive active tDCS stimulation with their cognitive training during a one-hour session each day which includes 20 minutes of stimulation at the beginning of a 46-minute task training session. Ten sessions will be completed over three weeks.

Device: Active Transcranial Direct Current Stimulation (tDCS)
Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.

Sham Comparator: Sham tDCS with Cognitive Training

Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 seconds, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.

Device: Sham Transcranial Direct Current Stimulation (tDCS)
Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)

Outcome Measures

Primary Outcome Measures

  1. Change in task impulsivity as measured by the NIH Flanker [Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)]

    Differences in the magnitude of change in NIH Flanker Reaction Time (RT) (ms) between active and sham groups from baseline to follow up sessions.

  2. Change in weight [Change between baseline and Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)]

    Differences in the magnitude of change in weights (kg) between active and sham tDCS (active from baseline to follow up sessions.

Secondary Outcome Measures

  1. Change in reported impulsivity as measured by the Barratt Impulsiveness Scale (BIS) [Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)]

    Differences in the magnitude of change in BIS scores (Likert scale points) will be compared between active and sham tDCS groups from baseline to follow up sessions.

  2. Change in reported impulsivity as measured by the UPPS-P Impulsive Behavior Scale (UPPS-P) [Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)]

    Differences in the magnitude of change in UPPS-P scores (Likert scale points) will be compared between active and sham tDCS groups from baseline to follow up sessions.

  3. Change in reported binge eating as measured by the Binge Eating Scale (BES) [Change between baseline and Visit 11, Visit 12 (approximately 2 months), and Visit 13 (approximately 4 months)]

    Differences in the magnitude of change in BES scores (Likert scale points) will be compared between active and sham tDCS groups from baseline to follow up sessions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Veteran enrolled in the MOVE! Weight Management Program at the Minneapolis VA Health Care System

  • Obese (BMI>30)

  • Adults, ages 18 years or older (up to age 80)

  • Able to understand English, self-consent and follow study-related procedures

  • Willing to use a reliable form of birth control if they are of females of child-bearing potential

Exclusion Criteria:
  • History of any of the following: seizures, severe or moderate head injury, head surgery, significant neurological disorder (significance based on Principal Investigator's judgment)

  • Frequent severe headaches

  • History of scalp conditions such as eczema or seborrheic dermatitis

  • Metal in head (other than in mouth) including shrapnel/surgical clips/welding fragments

  • Implanted medical devices (including pumps and cardiac pacemakers)

  • Pregnancy

  • Active substance abuse

  • Moderately severe to severe depression (as identified on PHQ-9 scale during baseline screening)

  • Other psychological or medical disorders requiring inpatient treatment (as identified during chart review)

  • Presence of a known metabolic or hormonal disorder (such as Cushing's, untreated thyroid dysfunction, or uncontrolled diabetes mellitus defined as a hemoglobin A1c > 8.0), or significant edema/volume overload - all of which would affect weight

  • History of hypothyroidism is acceptable if subject is on treatment with normal thyroid stimulating hormone (TSH) and FT4 on most recent check within the last 3 months and has been on stable dosage of l-thyroxine for at least 3 months, taking it as prescribed.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Minneapolis VA Health Care System, Minneapolis, MN Minneapolis Minnesota United States 55417

Sponsors and Collaborators

  • VA Office of Research and Development

Investigators

  • Principal Investigator: Shalamar D Sibley, MD, Minneapolis VA Health Care System, Minneapolis, MN

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT05225233
Other Study ID Numbers:
  • NURA-009-21S
First Posted:
Feb 4, 2022
Last Update Posted:
Jul 5, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2022